{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:03:09Z","timestamp":1783980189663,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000058","name":"Substance Abuse and Mental Health Services Administration","doi-asserted-by":"publisher","award":["1H79TI083288"],"award-info":[{"award-number":["1H79TI083288"]}],"id":[{"id":"10.13039\/100000058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000058","name":"Substance Abuse and Mental Health Services Administration","doi-asserted-by":"publisher","award":["H79TI085747"],"award-info":[{"award-number":["H79TI085747"]}],"id":[{"id":"10.13039\/100000058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004925","name":"Texas Health and Human Services Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.japh.2023.06.010","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T12:13:45Z","timestamp":1686917625000},"page":"1558-1565.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Independent community pharmacists\u2019 attitudes and intentions toward dispensing buprenorphine\/naloxone for opioid use disorder"],"prefix":"10.1016","volume":"63","author":[{"given":"Rana","family":"Zalmai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5958-0159","authenticated-orcid":false,"given":"Lucas G.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7969-5209","authenticated-orcid":false,"given":"Lindsey J.","family":"Loera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinn","family":"Mosgrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2S suppl 1","key":"10.1016\/j.japh.2023.06.010_bib1","first-page":"1","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update","volume":"14","year":"2020","journal-title":"J\u00a0Addict Med"},{"issue":"8","key":"10.1016\/j.japh.2023.06.010_bib5","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1034\/j.1399-6576.2003.00201.x","article-title":"Serious overdoses involving buprenorphine in Helsinki","volume":"47","author":"Boyd","year":"2003","journal-title":"Acta Anaesthesiol Scand"},{"issue":"2","key":"10.1016\/j.japh.2023.06.010_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jemermed.2012.11.104","article-title":"Medical outcomes associated with nonmedical use of methadone and buprenorphine","volume":"45","author":"Lee","year":"2013","journal-title":"J\u00a0Emerg Med"},{"issue":"3","key":"10.1016\/j.japh.2023.06.010_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"9358","key":"10.1016\/j.japh.2023.06.010_bib8","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial","volume":"361","author":"Kakko","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.japh.2023.06.010_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.japh.2023.06.010_bib10","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.japh.2023.06.010_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugalcdep.2018.09.007","article-title":"Understanding the use of diverted buprenorphine","volume":"193","author":"Cicero","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.japh.2023.06.010_bib12","first-page":"95","article-title":"Assessing motivations for nonprescribed buprenorphine use among rural Appalachian substance users","volume":"17","author":"McDonald","year":"2023","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.japh.2023.06.010_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109518","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states","volume":"237","author":"Hill","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"10.1016\/j.japh.2023.06.010_bib15","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/add.15314","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA","volume":"116","author":"Hill","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.japh.2023.06.010_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108729","article-title":"Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden","volume":"224","author":"Kazerouni","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2023.06.010_bib17","article-title":"Rural community pharmacist willingness to dispense Suboxone\u00ae-a secret shopper investigation in South-Central Appalachia","volume":"4","author":"Trull","year":"2021","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"1","key":"10.1016\/j.japh.2023.06.010_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12954-022-00651-3","article-title":"Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic","volume":"19","author":"Dadiomov","year":"2022","journal-title":"Harm Reduc J"},{"issue":"1","key":"10.1016\/j.japh.2023.06.010_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13722-022-00346-x","article-title":"Availability of medications for opioid use disorder in outpatient and inpatient pharmacies in South Florida: a secret shopper survey","volume":"17","author":"Syros","year":"2022","journal-title":"Addict Sci Clin Pract"},{"key":"10.1016\/j.japh.2023.06.010_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102701","article-title":"Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky","volume":"85","author":"Cooper","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"4","key":"10.1016\/j.japh.2023.06.010_bib21","first-page":"272","article-title":"DEA disconnect leads to buprenorphine bottlenecks","volume":"15","author":"Ostrach","year":"2021","journal-title":"J\u00a0Addict Med"},{"issue":"2","key":"10.1016\/j.japh.2023.06.010_bib22","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.japh.2021.10.002","article-title":"Ensuring buprenorphine access in rural community pharmacies to prevent overdoses","volume":"62","author":"Ostrach","year":"2022","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"1","key":"10.1016\/j.japh.2023.06.010_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jac5.1124","article-title":"Pharmacist involvement in combating the opioid crisis: a mixed-methods approach revealing conflicting perceptions","volume":"3","author":"Blue","year":"2020","journal-title":"J\u00a0Am Coll Clin Pharm"},{"issue":"5","key":"10.1016\/j.japh.2023.06.010_bib24","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.japh.2022.04.019","article-title":"North Carolina community pharmacists\u2019 buprenorphine dispensing practices and attitudes","volume":"62","author":"Carpenter","year":"2022","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"4","key":"10.1016\/j.japh.2023.06.010_bib25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/dar.12032","article-title":"Factors influencing pharmacy services in opioid substitution treatment","volume":"32","author":"Chaar","year":"2013","journal-title":"Drug Alcohol Rev"},{"issue":"2","key":"10.1016\/j.japh.2023.06.010_bib26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1037\/a0022776","article-title":"Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration","volume":"25","author":"Gordon","year":"2011","journal-title":"Psychol Addict Behav"},{"issue":"Suppl 3","key":"10.1016\/j.japh.2023.06.010_bib27","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","article-title":"Barriers and facilitators to the use of medications for opioid use disorder: a rapid review","volume":"35","author":"Mackey","year":"2020","journal-title":"J\u00a0Gen Intern Med"},{"issue":"1","key":"10.1016\/j.japh.2023.06.010_bib28","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.japh.2022.08.017","article-title":"Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: a national survey of community-based pharmacists","volume":"63","author":"Hill","year":"2023","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"2","key":"10.1016\/j.japh.2023.06.010_bib29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0749-5978(91)90020-T","article-title":"The theory of planned behavior","volume":"50","author":"Ajzen","year":"1991","journal-title":"Organ Behav Hum Decis Processes"},{"issue":"12","key":"10.1016\/j.japh.2023.06.010_bib30","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1080\/10826084.2022.2112226","article-title":"Barriers and facilitators to DATA waivered providers prescribing buprenorphine: a qualitative analysis applying the theory of planned behavior","volume":"57","author":"Bapat","year":"2022","journal-title":"Subst Use Misuse"},{"issue":"3","key":"10.1016\/j.japh.2023.06.010_bib31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/17437199.2014.941722","article-title":"Theories of behaviour and behaviour change across the social and behavioural sciences: a scoping review","volume":"9","author":"Davis","year":"2015","journal-title":"Health Psychol Rev"},{"key":"10.1016\/j.japh.2023.06.010_bib32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s43058-020-00050-4","article-title":"Predicting implementation: comparing validated measures of intention and assessing the role of motivation when designing behavioral interventions","volume":"1","author":"Fishman","year":"2020","journal-title":"Implement Sci Commun"},{"issue":"3S","key":"10.1016\/j.japh.2023.06.010_bib33","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.japh.2020.01.001","article-title":"Indiana community pharmacist preceptors' knowledge and perceptions of medication-assisted treatment","volume":"60","author":"Davenport","year":"2020","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"1","key":"10.1016\/j.japh.2023.06.010_bib34","first-page":"23","article-title":"Perceived barriers and facilitators to providing methadone maintenance treatment among rural community pharmacists in Southwestern Ontario","volume":"34","author":"Fonseca","year":"2018","journal-title":"J\u00a0Rural Health"},{"issue":"1","key":"10.1016\/j.japh.2023.06.010_bib35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/ajad.12982","article-title":"Physician and pharmacist: attitudes, facilitators, and barriers to prescribing naloxone for home rescue","volume":"29","author":"Martino","year":"2020","journal-title":"Am J Addict"},{"issue":"12","key":"10.1016\/j.japh.2023.06.010_bib36","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/add.13517","article-title":"Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal","volume":"111","author":"Nielsen","year":"2016","journal-title":"Addiction"},{"issue":"7","key":"10.1016\/j.japh.2023.06.010_bib37","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/10826084.2021.1906280","article-title":"Linking MATTERS: barriers and facilitators to implementing emergency department-initiated buprenorphine-naloxone in patients with opioid use disorder and linkage to long-term care","volume":"56","author":"Sokol","year":"2021","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.japh.2023.06.010_bib38","author":"Ajzen"},{"key":"10.1016\/j.japh.2023.06.010_bib39","author":"Home"},{"key":"10.1016\/j.japh.2023.06.010_bib42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.drugalcdep.2018.03.032","article-title":"Predicting pharmacy naloxone stocking and dispensing following a statewide standing order, Indiana 2016","volume":"188","author":"Meyerson","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.japh.2023.06.010_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1331\/1544345052843200","article-title":"Pharmacists\u2019 and technicians\u2019 perceptions and attitudes toward dispensing buprenorphine\/naloxone to patients with opioid dependence","volume":"45","author":"Raisch","year":"2005","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"1","key":"10.1016\/j.japh.2023.06.010_bib44","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.japh.2022.08.027","article-title":"Understanding the role of community pharmacies in current medication for opioid use disorder care practices","volume":"63","author":"Comanici","year":"2023","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"4","key":"10.1016\/j.japh.2023.06.010_bib45","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.japh.2018.04.025","article-title":"Identifying barriers to dispensing naloxone: a survey of community pharmacists in North Carolina","volume":"58","author":"Rudolph","year":"2018","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"2S","key":"10.1016\/j.japh.2023.06.010_bib46","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.japh.2016.12.064","article-title":"Pharmacists\u2019 role in opioid overdose: Kentucky pharmacists\u2019 willingness to participate in naloxone dispensing","volume":"57","author":"Freeman","year":"2017","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"3","key":"10.1016\/j.japh.2023.06.010_bib47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.sapharm.2006.02.008","article-title":"Prediction of pharmacist intention to provide Medicare medication therapy management services using the theory of planned behavior","volume":"2","author":"Herbert","year":"2006","journal-title":"Res Social Adm Pharm"},{"issue":"1","key":"10.1016\/j.japh.2023.06.010_bib48","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2125.2011.03944.x","article-title":"Influence of attitudes on pharmacists\u2019 intention to report serious adverse drug events to the Food and Drug Administration","volume":"72","author":"Gavaza","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.japh.2023.06.010_bib49","first-page":"239","article-title":"Community perceptions of comprehensive harm reduction programs and stigma towards people who inject drugs in rural Virginia","volume":"45","author":"Baker","year":"2020","journal-title":"J\u00a0Community Health"},{"key":"10.1016\/j.japh.2023.06.010_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108488","article-title":"Experiences of stigma among individuals in recovery from opioid use disorder in a rural setting: a qualitative analysis","volume":"130","author":"Burgess","year":"2021","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.japh.2023.06.010_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103703","article-title":"\u2018Red Flags\u2019 and \u2018Red Tape\u2019: telehealth and pharmacy-level barriers to buprenorphine in the United States","author":"Textor","year":"2022","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.japh.2023.06.010_bib52","article-title":"Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use","volume":"5","author":"Winstanley","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"issue":"5","key":"10.1016\/j.japh.2023.06.010_bib53","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/02602930301674","article-title":"Effectiveness of valid mean substitution in treating missing data in attitude assessment","volume":"28","author":"Dodeen","year":"2003","journal-title":"Assess Eval Higher Educ"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123001905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123001905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:29:49Z","timestamp":1778617789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319123001905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1544319123001905"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2023.06.010","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Independent community pharmacists\u2019 attitudes and intentions toward dispensing buprenorphine\/naloxone for opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2023.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}